Dr. Hill on the Challenges of Managing Heavily Pretreated DLBCL

Supplements And Featured Publications, Year in Review: Updates in DLBCL Treatment, Volume 1, Issue 1

Partner | Cancer Centers | <b>Cleveland Clinic</b>

Brian T. Hill, MD, PhD, discusses the challenges of managing heavily pretreated patients with diffuse large B-cell lymphoma.

Brian T. Hill, MD, PhD, director of the Lymphoid Malignancies Program and staff physician, Taussig Cancer Institute, and assistant professor, Hematology and Oncology, Cleveland Clinic, discusses the challenges of managing heavily pretreated patients with diffuse large B-cell lymphoma (DLBCL).

Patients with DLBCL who progress on frontline therapy are considered to be high risk for additional treatment failure and poor survival, Hill explains.

Autologous stem cell transplant, as well as CAR T-cell therapy which has been introduced more recently, offer 2 potential options for heavily pretreated patients with DLBCL, says Hill.

However, beyond these therapies, which are considered to be relatively intensive treatment modalities, patients have limited options, concludes Hill.